Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Completed · Phase 1

Conditions studied: Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL), Leukemia, Lymphoma

In brief

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Key facts

Study ID

NCT00647764

Run by

Esanex Inc.

People needed

32

Starts

2008-03-01

Expected to finish

2010-09-01

Last updated by the study team

2012-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Solid tumors or lymphoid malignancies refractory to standard therapy
• measurable disease
• recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy
• no chemotherapy within 4 weeks of entering study
• Age > 18 years
• Karnofsy >= 60%
• Life expectancy > 3 months
• normal or adequate organ and marrow function

You may not qualify if…

• receiving other investigational agents
• brain metastases
• uncontrolled medical illness
• HIV+ receiving combination antiretroviral therapy
• significant GI disease

Where it is running

• Pfizer Investigational Site — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.